Liver cancer Cancer Malignant neoplasm of liver and intrahepatic bile ducts
Conditions
Interventions
The study aims are to understand the immune changes that occur in patients with liver disease that promote the development of liver cancer. With this information, the researchers aim to identify novel
Sponsors
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients will be over 18 years of age 2. The recruited patients will have primary liver cancer, secondary liver cancer or chronic liver disease 3. Patients will be attending the Newcastle upon Tyne NHS Foundation Trust, or one of the collaborating centres, for consideration of liver related treatment 4. The patient will be willing and able to provide written informed consent to take part in the study
Exclusion criteria
Exclusion criteria: 1. Patients who have received previous treatment for HCC, unless recruited just prior to starting 2nd line treatment 2. Patients deemed too distressed or unwell to approach about taking part in the research project 3. Patients who lack capacity to give informed consent 4. Patients who are not able to undertake study procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient survival measured in months after diagnosis of HCC | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Radiological response to treatment measured using CT scans 1 month after treatment, and 3-monthly thereafter 2. Clinical response to treatment measured using clinical assessment and blood tests 1 month after treatment, and 3-monthly thereafter 3. Time to radiological progression measured using CT scans at 1-3 monthly intervals 4. Time to clinical progression measured using outpatient visits at 1-3 monthly intervals 5. Time to recurrence measured using CT scans at 1-3 monthly intervals | — |
Countries
England, Scotland, United Kingdom
Outcome results
None listed